Development of a novel molecular target therapy that can suppress melanoma progression
| Project/Area Number |
26670525
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
Masashi Kato 名古屋大学, 医学系研究科, 教授 (10281073)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
武田 湖州恵 中部大学, 生命健康科学部, 准教授 (80345884)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAJIMA Ichiro 名古屋大学, 医学系研究科, 講師 (80469022)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | メラノーマ / バイオマーカー / 分子標的療法 / 動物モデル / BRAF変異 / RET / RET-マウス / DTX3L / 免疫療法 / LSF / p21 / 国際情報交換 / モデル動物 |
|---|
| Outline of Final Research Achievements |
We previous developed RET-transgenic mice (RET-mice), in which development of hyperpigmented skin and benign melanocytic tumors at about 100% and development of melanoma at about 65%. In this study, we first selected molecules after performing microarray analysis using benign tumor and melanoma developed in RET-mouse. We then performed functional analysis for these three molecules. The molecules are involved in the regulation for anchorage- independent growth, invasion and metastasis. Thus, we have not only proposed plural candidate molecules that are available as a biomarker of melanoma but also provided basic data for developing a molecular target therapy that suppress melanoma proliferation, infiltration and metastasis.
|
Report
(4 results)
Research Products
(45 results)
-
-
-
-
-
-
-
-
[Journal Article] A comprehensive study including monitoring, assessment of health effects and development of a remediation method for chromium pollution2018
Author(s)
Yoshinaga M, Ninomiya H, Al Hossain MMA, Sudo M, Akhand AA, Ahsan N, Alim MA, Khalequzzaman M, Iida M, Yajima I, Ohgami N, Kato M.
-
Journal Title
Chemosphere
Volume: 201
Pages: 667-75
DOI
NAID
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
[Journal Article] Transcription factor LSF (TFCP2) inhibits melanoma growth.2016
Author(s)
Goto Y, Yajima I, Kumasaka M, Ohgami N, Tanaka A, Tsuzuki T, Inoue Y, Fukushima S, Ihn H, Kyoya M, Ohashi H, Kawakami T, Bennett DC, Kato M.
-
Journal Title
Oncotarget.
Volume: 19
Issue: 3
Pages: 2739-2790
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
[Journal Article] The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells2014
Author(s)
F. Vegran, H. Berger, R. Boidot, G. Mignot, M. Bruchard, M. Dosset, F. Chalmin, C. Rebe, V. Derangere, B. Ryffel, M. Kato, A. Prevost-Blondel, F. Ghiringhelli, L. Apetoh
-
Journal Title
Nature Immunology
Volume: 15
Issue: 8
Pages: 758-766
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Melanoma-Initiating Cells Exploit M2 Macrophage TGF.2014
Author(s)
Tham M, Tan KW, Keeble J, Wang X, Hubert S, Barron L, Tan NS, Kato M, Prevost-Blondel A, Angeli V, Abastado J-P.
-
Journal Title
Oncotarget
Volume: 5
Pages: 12027-42
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
